register

News & Trends - MedTech & Diagnostics

Charting sovereign capability in diagnostics: PTA and MTPConnect join forces on policy implications

Health Industry Hub | September 13, 2023 |

MedTech & Diagnostics News: Dr Dharmica Mistry, Director of Diagnostics Industry Engagement at MTPConnect, and Dean Whiting, CEO of Pathology Technology Australia (PTA), joined Health Industry Hub to discuss the evolution of the diagnostics sector in Australia over the past decade and its critical contributions to patient care. They delved into the vulnerabilities exposed by the COVID-19 pandemic in Australia’s reliance on international suppliers for diagnostic products and the importance of addressing this issue.

Mr Whiting emphasised a striking reality: a staggering 97% of diagnostics utilised in Australia are imported.

“Around 30% of our supply chain for diagnostic products come through the Indo Pacific region. If you think about the potential geopolitical disturbances in that region, we don’t need to wait for the next pandemic to have potential supply chain challenges. We need to be thinking about this now, acting on it now and and starting to solve these problems now,” commented Mr Whiting.

The interview covered insights from the recently launched ADAPT report, highlighting extensive consultations with healthcare sector experts. The duo shared major challenges and opportunities identified during these consultations, shedding light on the current state of diagnostic capabilities in Australia.

“This is the first time we’ve investigated where the diagnostic products are coming into Australia and what our supply chain risks are. The data highlights the importance of what’s missing and how we need to be more prepared and somewhat self sufficient,” remarked Dr Mistry.

Furthermore, the interview explored the key recommendations outlined in the ADAPT report to enhance diagnostic capability and establish sovereign manufacturing capabilities within the country.

As for the next steps in implementing these recommendations, the Mr Whiting and Dr Mistry addressed potential policy and funding barriers that may arise. They outlined the strategies for overcoming these obstacles and ensuring the successful execution of the proposed improvements in the diagnostics sector.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Government's rejection of COVID Royal Commission a stark contrast to the UK and NZ

Government’s rejection of COVID Royal Commission a stark contrast to the UK and NZ

Health Industry Hub | September 20, 2024 |

The Albanese government has dismissed the Senate legal and constitutional committee’s proposal for a COVID-19 pandemic royal commission with one […]

More


News & Trends - Biotechnology

AusBiotech and MTPConnect Unite for Landmark Summit on Australia’s Biotech and Medtech Future

AusBiotech and MTPConnect unite for landmark Summit on the nation’s biotech and medtech future

Health Industry Hub | September 20, 2024 |

AusBiotech and MTPConnect have announced an ambitious new collaboration to host Australia’s first National Biotech and Medtech Development and Commercialisation […]

More


ESG

Wear It Red Day ignites national movement for chronic pain recognition, demanding voices be heard

Wear It Red Day ignites national movement for chronic pain recognition, demanding voices be heard

Health Industry Hub | September 20, 2024 |

Today marks the first ever national Wear It Red Day. An initiative of Painaustralia, the national peak advocacy body for […]

More


News & Trends - Pharmaceuticals

Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients

Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients: New study

Health Industry Hub | September 20, 2024 |

Pharma News: New research from the led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) […]

More


This content is copyright protected. Please subscribe to gain access.